Lunglife AI, Inc. engages in the development of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence enabled molecular analysis of cancer biomarkers in blood. Its diagnostic test, LungLB, is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules. It operates through the People’s Republic of China and United States of America geographical segments. The company was founded by Frederick W. Gluck, Alan J. Heeger2, and Hyongsok Soh in 2008 and is headquartered in Thousand Oaks, CA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company